PODCAST · health
OncTimes Talk
by Oncology Times
OncTimes Talk features a variety of podcast series ranging from breaking news and oncology conference coverage to story round-ups and in-depth interviews with current experts and leaders in oncology.
Episodes
-
Tumor-Specific Immunotherapy for Patients with High-Risk Melanoma: The Potential Role of mRNA Cancer Vaccines
Since the release of 5-year follow-up data from the Phase IIb KEYNOTE-942 study, in which the mRNA vaccine intismeran autogene is used in combination with pembrolizumab to treat high-risk resected melanoma, the potential of new and more effective immune therapies for solid tumors has been...
-
The Future of Cancer Research: Clinical Trials, AI & Access to Care
In this episode of OncTimes Talk, Karen Knudsen, MBA, PhD, CEO of the Parker Institute for Cancer Immunotherapy, discusses barriers to clinical trial participation, the promise of AI in oncology, and the challenges facing cancer research funding. She explores why patient voices, equitable access,...
-
Targeting Tumor Acidity With Topical Bicarbonate Therapy
Dr. Shari Pilon-Thomas joins OncTimes Talk to discuss groundbreaking findings published in Frontiers in Immunology showing that topical bicarbonate treatment can counteract tumor acidosis and enhance anti-tumor immune responses. The conversation explores the science behind acidic tumor...
-
Rethinking Breast Cancer Screening
In this episode of OncTimes Talk, Dr. Susan MacDonald interviews Dr. Barbara Levy about the evolution of breast cancer screening. Together, they discuss balancing early detection with overtesting, empowering patients to advocate for themselves, and designing healthcare systems that put people first.
-
Inside Lytix Biopharma's Breakthrough in Immunotherapy
In this episode, we explore how Lytix Biopharma is advancing a new kind of cancer treatment designed to both destroy tumors and train the immune system to fight back. Dr. Øystein Rekdal joins Dr. Susan McDonald to discuss the science behind LTX-315, a first-in-class oncolytic peptide, and its...
-
A Lap Around the Couch: Why Exercise Matters in Cancer Care
In this episode, Kathryn Schmitz, PhD, MPH, explains why movement should be treated like medicine for patients with cancer. In conversation with Susan MacDonald, MD, she breaks down the evidence, addresses common barriers, and offers practical guidance for both clinicians and patients. Resources...
-
Understanding the Rise in Early-Onset Cancer
In this episode of Oncology Times, Dr. Susan MacDonald speaks with epidemiologist Dr. Mary Beth Terry about the alarming rise in early-onset cancers, particularly among women, and the role of environmental and lifestyle factors. They explore emerging evidence on alcohol use, plastics, vaping, and...
-
Championing Community Cancer Care
In this episode of OncTimes Talk, host Dr. McDonald speaks with Rose Gerber, Director of Patient Advocacy and Education at the Community Oncology Alliance (COA) and a 23‑year breast cancer survivor. Rose shares her powerful personal cancer journey and how that experience ignited her lifelong...
-
Radioactive Resilience: A Survivor's Mission to Cure Cancer
What happens when you survive a disaster that steals the lives of thousands of children? For Dr. Yan Leyfman, surviving Chernobyl as a child wasn't just fate—it became the foundation of a lifelong mission to heal. In this deeply personal conversation, Yan shares how tragedy shaped his calling in...
-
Results from OncoExTra® Testing of 10K Tumor Samples Show the Next Generation of Sequencing
In this podcast episode, Dr. Christine Ibilibor meets with Dr. Jean-Paul De La O, a Senior Principal Medical Affairs Director at Exact Sciences, to talk about how comprehensive DNA and RNA sequencing of tumors has become easier, faster and more actionable for oncologists. The pair also discuss...
-
The Evolving Landscape of Bladder Cancer
In this episode of OncTimes Talk, we chat with Dr. Janet Kukreja about the evolving landscape of bladder cancer.
-
The Current State of Skin Cancer in the U.S.
In this episode of OncTimes Talk, Dr. Victor Czerkasij, DNP, DCNP, FNP-C, CWCP, MSN, MA discusses the current state of skin cancer in the U.S.
-
United Theranostics and the Future of Cancer Care
In this episode of OncTimes Talk, we chat with Dr. Eliot Siegel, MD, FACR, FSIM, DABR; Dr. Michael Morris, MD, MS, DABR, DABNM, DCI; Dr. Babak Saboury, MD, MPH, DABR, DABNM; and Chief Medical Officer Dr. Munir Ghesani, MD, FACNM, FACR, FSNMMI from United Theranostics, a national leader in…
more -
Smashing Plates, Facing Fear: Heather Von St. James' Journey
At 36, Heather Von St. James was diagnosed with malignant pleural mesothelioma and given just 15 months to live. Nineteen years later, she's not only surviving, but she's also leading a movement. In this episode, Heather shares how she turned trauma into purpose, created a powerful annual ritual...
-
Joey-Rose Jester on Life with Cholangiocarcinoma: A Conversation About Cancer, Work, and Everything in Between
In this episode of OncTimes Talk, we chat with Joey-Rose Jester, an exhibits manager and survivor of cholangiocarcinoma to explore the personal and professional sides of her cancer journey. From navigating a rare diagnosis to showing up at work during treatment, Joey-Rose shares honest…
more -
From Ironman to Advocate: Tom Hulsey's Journey Through Prostate Cancer and Purpose
In this episode of OncTimes Talk, we chat with Tom Hulsey—athlete, author, and prostate cancer survivor—about the life-altering moment he received his diagnosis on his birthday, and how it set him on a path of resilience, advocacy, and renewed purpose. Tom opens up about the emotional toll of...
-
Accurate and Actionable: How Oncologists Get Fast, Comprehensive Therapeutic Insights from the OncoExTra® Test
In this third episode of the OncoExTra® podcast series, host Ruchika Talwar, MD, talks with Christy Russell, MD, Vice President of Medical Affairs at Exact Sciences, about what oncologists can expect when they receive their OncoExTra comprehensive genomic profiling test results, and how they can...
-
Empowering Cancer Care Through Movement: A Conversation with Sami Mansfield
In this episode of OncTimes Talk, we chat with Sami Mansfield, ACSM-CET, PN1, the founder of Cancer Wellness for Life, an organization dedicated to developing, implementing, and optimizing exercise oncology and lifestyle medicine programs and resources for hospitals, healthcare organizations,...
-
Defying the Odds: Katie Colman's Journey from Diagnosis to Advocacy
In this episode of OncTimes Talk, we chat with Katie Colman. Diagnosed with an ultra-rare stage IV kidney cancer in 2020, her prognosis had a chance to significantly change after six months. Since then, Katie has since become an Author, founded a non-profit organization, and has become a podcast...
-
Making Comprehensive Genomic Profiling More Accurate for Everyone: The Importance of Patient-Matched Tumor-Normal Sequencing
In this podcast episode, host Ruchika Talwar, MD, is joined by Amin Mazloom, PhD, Senior Vice President of Bioinformatics, Biostatistics & Data Innovation, and Janine LoBello, DO, Senior Clinical Laboratory Medical Director at Exact Sciences to discuss patient-matched tumor-normal (PMTN)…
more -
Patient-Matched Tumor-Normal Sequencing: What It Is and Why It Matters
In this podcast episode, host Ruchika Talwar, MD, is joined by Amin Mazloom, PhD, Senior Vice President of Bioinformatics, Biostatistics & Data Innovation, and Janine LoBello, DO, Senior Clinical Laboratory Medical Director at Exact Sciences to discuss patient-matched tumor-normal (PMTN)…
more -
Transforming colorectal cancer management with tumor informed ctDNA testing
In this episode, Dr. Ruchika Talwar, a urologic oncologist at Vanderbilt University Medical Center, Dr. Adham Jurdi, a medical oncologist and Senior Director of Oncology at Natera, delve into the groundbreaking world of tumor-informed molecular residual disease testing. Discover how circulating...
-
Lessons in Resilience: Dr. Susan MacDonald's Healthcare Journey
In this episode of the OncTimes Talk, we chat with Susan MacDonald, MD, Associate Professor and Program Director of the Department of Urology at Penn State Health Milton S. Hershey Medical Center, in Hershey, PA. MacDonald shares her inspiring journey of facing a life-changing diagnosis with...
-
Mobile Prostate Cancer Screening Clinic Raises Prostate Cancer Early Detection Rates in Underserved Communities at High Risk
Masood Moghul, MBBS, a urologist and Research Fellow at the Royal Marsden Hospital and Institute of Cancer Research in London shared findings from a study investigating a mobile, targeted, case-finding approach to prostate cancer detection with 3,379 patients. Moghul told the 2025 American…
more -
Episode 3, Better Informed Patient Journeys
In the third episode of A Deep Dive Into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we're speaking with Dr. David O'Malley, and Bobbie R, an ovarian cancer patient. Dr. O'Malley will highlight how HRD testing empowers ovarian cancer patients to make more...
-
Episode 2, HRD Testing Deep-Dive
In the second episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we're speaking with Dr. Erin Crane who will highlight how HRD testing provides helpful information to ovarian cancer patients. Erin K. Crane, MD, MPH, is a gynecologic...
-
Episode 1, A Precision Medicine Approach for Advanced Ovarian Cancer
In the first episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we're speaking with Dr. Kathleen Moore about HRD testing in ovarian cancer and its clinical significance in helping aid precision medicine approaches. Dr. Kathleen Moore…
more -
Striking Microbiome Bacterial Population Differences Distinguish Metastatic Prostate Cancer From Non-Metastatic Disease
At the 2025 ASCO Genitourinary Cancers Symposium, researchers from Japan reported marked differences between the populations of several key microbial species in the gut microbiomes of patients with metastatic prostate cancer that distinguished them from those with non-metastatic disease. This was...
-
Adjuvant Androgen Deprivation Therapy No Benefit After Surgery for High-Risk Prostate Cancer
At the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, the Phase III AFU-GETUG-20 trial reported that adjuvant androgen deprivation therapy did not improve outcomes when added to surgery for patients with high-risk prostate cancer. Using 2 years of androgen deprivation therapy after...
-
Novel Score Selects Patients With Intermediate Risk Prostate Cancer Safe for Active Surveillance
A numerical formula called the absolute percentage pattern 4/5 (APP4) combining risk factors, including Gleason grade, PSA, and digital rectal examination, is being used to select patients whose intermediate risk prostate cancer can safely be followed with active surveillance. A research study...
-
Mobile Prostate Cancer Screening Clinic Raises Prostate Cancer Early Detection Rates in Underserved Communities
Masood Moghul, MBBS, a urologist and research fellow at the Royal Marsden Hospital and Institute of Cancer Research in London, UK, discussed his group's findings from the Man Van study investigating a mobile, targeted, case-finding approach to prostate cancer detection with 3,379 patients…
more -
KEYNOTE-006 Study 10-Year Survival Data Confirm PD-L1 Checkpoint Inhibition Best for Patients With Advanced Melanoma
The pivotal role of programmed death-ligand 1 (PD-L1) checkpoint inhibition for treating advanced melanoma has been confirmed in findings from the KEYNOTE-006 study comparing the anti-PD-L1 antibody pembrolizumab immunotherapy with the anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4)…
more -
Microsatellite Unstable Colorectal Cancers: Key Gene Mutation for Werner Helicase Inhibitor Resistance Identified
Although one in five colorectal cancers having microsatellite instability and expressing the Werner Helicase (WRN) gene could be treated with drugs that inhibit WRN, the effectiveness of such an approach has been limited by resistance. However, researchers identified the Cys727 mutation as being...
-
Microsatellite Unstable Colorectal Cancers: Key Gene Mutation for Werner Helicase Inhibitor Resistance Identified
The pivotal role of programmed death-ligand 1 (PD-L1) checkpoint inhibition for treating advanced melanoma has been confirmed in findings from the KEYNOTE-006 study comparing the anti-PD-L1 antibody pembrolizumab immunotherapy with the anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4)…
more -
Tumor-Agnostic Classifier & Screener Aids Targeted Drug Development
A tumor-agnostic classifier and screening tool was announced at ESMO Congress 2024 in Barcelona. It was created to make it easier and quicker to develop new drugs that have specific molecular targets, and thus have potential anti-cancer efficacy irrespective of tumor type or location. The ESMO...
-
Early Switch to Immunotherapy Recommended After BRAFV600 Mutation Targeted Therapy for Advanced Melanoma
Findings from a study of patients receiving targeted therapy for their BRAFV600 mutation-positive advanced melanoma, suggest that switching early to immune checkpoint inhibition appeared to bring better rates of overall survival than saving immunotherapy for use as salvage treatment later on. The...
-
Clear Benefit From Early Checkpoint Inhibition in Locally Advanced, High-Risk Cervical Cancer
A clinically meaningful benefit in overall survival was found in the second interim analysis of the randomized, double-blind, Phase III KEYNOTE-A18 study of immunotherapy together with concurrent chemoradiotherapy among 1,060 patients who had newly diagnosed, previously untreated high-risk…
more -
The New Standard: Testing for All Therapy-Matched DNA and RNA Biomarkers Up Front
In this podcast episode, Ruchika Talwar, MD, sits down with Rick Baehner, MD, Chief Medical Officer of Precision Oncology at Exact Sciences and Clinical Professor of Pathology at University of California, San Francisco, to discuss the importance of ultra-comprehensive genomic profiling in…
more -
Digital Twin Brings AI Power to Individualize Cancer Management
The prospect of markedly raising chemotherapy response rates and extending patient survival has been held out by scientists reporting a new AI-powered digital tool to optimize cancer management for individual patients. The tool creates a "digital twin" for each patient that makes it possible to...
-
Wnt Signaling Pathway Inhibitor Suggests Toxicity-Free Cure Potential for Hepatoblastoma
The prospect of a minimally toxic, chemotherapy-free cure for hepatoblastoma is held out by findings from a mouse model using the small-molecule drug WNTinib that inhibits the Wnt signaling pathway involved with cancer growth. Lead author Ugnė Balaševičiūtė, a pre-doctoral researcher in...
-
Anti-HER2 Combination Found Effective in HER2-Altered Bile Duct Cancers
A chemotherapy-free combination of two anti-human epidermal growth factor receptor 2 (anti-HER2) agents brought clinically meaningful responses to patients with bile duct cancers testing positive for HER2 or with mutated HER2 in research from Japan reported at the EORTC-NCI-AACR 2024 Molecular...
-
FGFR-3 Inhibitor Has Early Clinical Activity in Advanced Urothelial Cancer
The fibroblast growth factor receptor-3 (FGFR-3) inhibitor TYRA-300 has been found safe with dose-dependent responses and disease control in the Phase I SURF301 trial. The study included 41 patients who had been heavily pre-treated for their advanced solid tumors with activating FGFR3...
-
Radiation Delivery by Mini Protein Brings Promise for Metastatic Urothelial & Other Solid Tumors
The mini-protein radiopharmaceutical AKY-1189, designed to deliver the alpha-emitting isotope Actinium-225 (225Ac) to tumors expressing the Nectin-4 transmembrane protein, has been found to achieve favorable dosing to tumors, while minimizing exposure to non-target tissues, including the kidney....
-
Antibody-Drug Conjugate "Promising Efficacy" in HER2-Positive and HER2-Low Breast Cancer
In a Phase I study with 318 patients in China and Australia the antibody-drug conjugate (ADC) IBI354 was found to be safe and have promising efficacy in patients whose breast and other solid tumors tested positive for HER2 or were categorized as "HER2-low." At ESMO Congress 2024, the study also...
-
Advanced Melanoma: CheckMate 067 10-Year Data Show Prognoses Transformed By Checkpoint Inhibitors
Sustained responses and long-term overall survival have resulted from checkpoint inhibitor therapy for advanced melanoma, transforming the prognosis for as many as half of patients. This is according to 10-year survival outcomes from the Phase Ill CheckMate 067 trial of nivolumab plus ipilimumab…
more -
Preoperative Chemoradiation Ruled Out for Gastric or GE Junction Resectable Adenocarcinoma
The addition of preoperative chemoradiation therapy to perioperative chemotherapy did not improve overall survival as compared with perioperative chemotherapy alone in patients with resectable gastric or gastroesophageal junction adenocarcinomas. The multi-continent, Phase III randomized TOPGEAR...
-
Perioperative Checkpoint Inhibition Better for Muscle-Invasive Bladder Cancer
Patients with muscle-invasive bladder cancer experienced "clinically meaningful" improvements in key outcomes—event-free survival and overall survival—when the immune checkpoint inhibitor durvalumab was added to their standard neoadjuvant chemotherapy. This was in research findings, reported at…
more -
Recurrent Glioma: Encouraging Responses to Autologous Myeloid Dendritic Cell Therapy
When patients with recurrent high-grade glioblastoma were treated with autologous myeloid dendritic cells, they had clinical responses described as "encouraging" in a Phase I clinical trial reported at the ESMO Congress 2024. Cells harvested from each patient were injected directly into the...
-
Therapeutic mRNA Vaccine Brings New Hope in Glioblastoma
Patients with newly diagnosed, surgically resected MGMT-unmethylated glioblastoma may benefit from treatment with a therapeutic mRNA vaccine called CVGBM, according to findings from a first-in-human, Phase I safety and dose-escalation study from Tübingen, Germany, reported at the ESMO Congress…
more -
Resectable Stage III Melanoma: Unprecedented Survival Benefit With Pure Checkpoint Inhibitor Neoadjuvant Therapy
A large, expanded-cohort pooled analysis of neoadjuvant immunotherapy for patients with resectable Stage III melanoma has reported very high rates of durable survival. The findings from the world's biggest center of expertise in melanoma were announced at ESMO Congress 2024. The study included...
We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.
No matches for "" in this podcast's transcripts.
No topics indexed yet for this podcast.
Loading reviews...
Loading similar podcasts...
Frequently Asked Questions
How many episodes does OncTimes Talk have?
OncTimes Talk currently has 100 episodes available on PodParley. New episodes are automatically indexed when they're published to the podcast feed.
What is OncTimes Talk about?
OncTimes Talk features a variety of podcast series ranging from breaking news and oncology conference coverage to story round-ups and in-depth interviews with current experts and leaders in oncology.
How often does OncTimes Talk release new episodes?
OncTimes Talk has 100 episodes. Check the episode list to see recent publication dates and frequency.
Where can I listen to OncTimes Talk?
You can listen to OncTimes Talk on PodParley by clicking any episode. We provide an embedded audio player for direct listening, and you can also subscribe via your preferred podcast app using the RSS feed.
Who hosts OncTimes Talk?
OncTimes Talk is created and hosted by Oncology Times.
URL copied to clipboard!